Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIT225 for early mild to moderate COVID-19
ACTRN12623000035628Phase 2Not yet recruiting
- Sponsor
- Biotron Ltd
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of BIT225 in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Biotron Ltd. Primary endpoints: Safety and tolerability of BIT225 versus placebo and Efficacy based on SARS-CoV-2 nasal viral load and time to PCR negativity. Planned start May 2023; status: not yet recruiting.
02
Drugs
BIT225
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ACTRN12623000035628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623000035628.